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Abstract
Background: Neoplastic transformation originates from a large number of different genetic alterations. Despite this genetic
variability, a common phenotype to transformed cells is cellular alkalinization. We have previously shown in human
keratinocytes and a cell line in which transformation can be turned on and followed by the inducible expression of the E7
oncogene of human papillomavirus type 16 (HPV16), that intracellular alkalinization is an early and essential physiological
event driven by the up-regulation of the Na/
+H
+ exchanger isoform 1 (NHE1) and is necessary for the development of other
transformed phenotypes and the in vivo tumor formation in nude mice.
Methodology: Here, we utilize these model systems to elucidate the dynamic sequence of alterations of the upstream
signal transduction systems leading to the transformation-dependent activation of NHE1.
Principal Findings: We observe that a down-regulation of p38 MAPK activity is a fundamental step in the ability of the
oncogene to transform the cell. Further, using pharmacological agents and transient transfections with dominant
interfering, constitutively active, phosphorylation negative mutants and siRNA strategy to modify specific upstream signal
transduction components that link HPV16 E7 oncogenic signals to up-regulation of the NHE1, we demonstrate that the
stimulation of NHE1 activity is driven by an early rise in cellular cAMP resulting in the down-stream inhibition of p38 MAPK
via the PKA-dependent phosphorylation of the small G-protein, RhoA, and its subsequent inhibition.
Conclusions: All together these data significantly improve our knowledge concerning the basic cellular alterations involved
in oncogene-driven neoplastic transformation.
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Introduction
Neoplastic transformation is the first step of the carcinogenic
process that involves the initial altered responses of the cells to
normal regulatory influences and sets the stage for further alterations
thatresultincarcinoma.Awidevarietyofalteredphenotypesappear
as a result of transformation. Hallmarks of epithelial transformation
and carcinogenesis include loss of polarity, as well as uncontrolled,
serum-independent and anchorage-independent proliferation and
resistance to apoptosis [1]. Other fundamental hallmarks of
epithelial carcinogenesis include an elevated intracellular pH (pHi)
as well as their increased rate of glucose utilization over oxidative
phosphorylation [2,3]. However, our understanding of the sequence
of early events mediating the initiation, development and regulation
of malignant transformation is still incomplete.
One major group of cellular signal transduction components
implicated in carcinogenesis are the mitogen-activated protein
kinases (MAPKs). Altered expression/activity of each of the
MAPKs such as ERK (extracellular signal-regulated kinase), JNK
(Jun N-terminal kinase) and p38 has been linked to tumor
progression in a wide variety of cellular contexts [4–6]. In
particular, mounting evidence indicates a negative role for the
p38alpha MAP Kinase in chemical-[7] and oncogene-[8] induced
tumor formation and proliferation [9], in tumor cell directed cell
polarity [10–12] and in malignant invasion [11,12]. Conversely, a
positive role of p38 has been shown in tumor suppression and
delay of tumorigenesis [13,14], in induction of apoptosis
[15,13,16], in a specific tumor-suppressing defense mechanism of
normal non transformed cells known as oncogene induction of
senescence, [17], in dormancy [18,19] and in the increased cell
viability and enhanced growth of HPV-induced recurrent
respiratory papillomatosis [20]. The importance of p38 as tumor
suppressor is highlighted by recent attempts to identify cancer-
associated mutations in protein kinase genes, which revealed that
several components of the p38 pathway, including p38alpha, are
mutated in human tumors [17]. Further, p38 is activated in cancer
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driven [23] apoptosis. In liver cells chemically induced to form
tumors, p38alpha negatively regulated tumor proliferation via a
repression of the JNK-c-Jun pathway [24].
While the negative role for p38alpha in regulating carcino-
genesis is well described, whether it plays a similar negative role
in the initiation of neoplastic transformation and through which
signaling pathways are still undetermined. In this context,
important questions concern if p38alpha plays a role in the
development of the initial transformed phenotype after oncogene
expression, what is its pattern of involvement and what are its
critical upstream and downstream components. Recent progress
suggests possible candidate signal transduction pathways. As a
regulator of gene expression, cell cycle progression and actin
cytoskeleton organization, it is now clear that RhoA, a member
of the Rho family of GTPases, plays a central role in
carcinogenesis and tumor progression [25–27]. Recent studies
indicate RhoA as a central upstream regulator of MAP kinase
activity [26,28–31] and specifically in breast cancer [11] and
pancreatic carcinoma [32] cells. Importantly, forced expression
of the E7 oncogene of HPV16 in keratinocytes has recently been
shown to inhibit RhoA activity although the mechanism is still
not completely clear [33].
The cAMP/PKA system has been demonstrated to be involved
in both transformation/tumor progression [11,34,35] proliferation
[35–37] and apoptosis [38–40]. This system is also involved in
regulating p38 activity [11,41–43] and there is evidence that direct
PKA-dependent phosphorylation of RhoA at Ser 188 inhibits its
activity in endothelial cells [44], in smooth muscle cells [45], in
cytotoxic lymphocytes [46] and in tumor cells [11] suggesting that
PKA and RhoA could regulate p38 activity through a common
pathway.
The goal of the present work is to determine which signal
transduction systems are involved in transformation driven by a
relevant oncogene. That little is known about the modifications
occuring in the regulatory pathways during malignant transfor-
mation has been due, in part, to the lack of experimental
models in which the transformation of normal cells by a
relevant oncogene can be finely controlled and followed [17].
Since the human papilloma viruses, especially HPV16, are the
prime cause of the majority of virus-associated carcinomas and
the E7 and E6 proteins are the viral proteins responsible for
malignant transformation [47], we chose the E7 oncogene of
HPV16 to create an experimental cell model useful for the
investigation of the alterations in signal transduction mecha-
nisms underlying the initial phases of the shift from the normal
to transformed state [48]. This cell model (2BN11 cells) consists
of normal NIH-3T3 fibroblasts stably transfected with the gene
for the HPV16 E7 oncoprotein in a vector in which its
expression is under the control of a tetracycline (tet) inducible
promoter such that the level of E7 expression and, therefore,
transformation can be tightly regulated. This inducible expres-
sion permits the repeated following of the time-dependent
development of the events in which the same cell constitutes its
own control. Using the 2BN11 model system, we previously
observed that intracellular alkalinization driven by an up-
regulation of the Na
+/H
+-exchanger (NHE1) is a very early
physiological event in transformation and is essential for the
development of other transformed phenotypes such as increased
glycolytic metabolism, increased growth rate and both serum-
independent and anchorage-independent growth [48]. Here, we
report that HPV16 E7-dependent transformation mediated by
NHE1 is driven by the action of a RhoA-p38alpha module
gated by the PKA dependent phosphorylation of RhoA.
Materials and Methods
Cell culture, transfections and reagents
NIH3T3 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) with 4.5 g of glucose per liter, supplemented
with 10% calf serum. Normal human foreskin keratinocytes
(HFKs) were isolated from neonatal foreskin as described
previously [49] and were maintained in keratinocyte growth
medium supplemented with bovine pituitary extract (Clonetics).
Primary human keratinocytes infected with HPV16 [50] and
cultured at low (HPK1a early) or high (HPK1A late) passage
numbers were maintained as previously described [48]. These cells
spontanously transform at high passages and high passage cells are
tumorgenic in nude mice [48].
High-titer retroviral supernatants (10
6 virus particles/ml) were
generated by transient transfection of Bosc23 cells (ecotropic
viruses) or Phoenix (amphotropic viruses) and used to infect the
cells as described previously [48]. Cells were grown to about 80%
confluence in a 10-cm-diameter dish and infected with 5 ml of the
recombinant retrovirus or parental virus in the presence of 8 mgo f
Polybrene per ml in order to enhance infection efficacy. After 6 h
infected cells were fed with complete medium and kept at 37uC
with 5% CO2 for 48 h. The cells were then transferred to four 10-
cm-diameter dishes and selected with 2.0 mg of puromycin/ml for
3 to 4 days. Selected cells were expanded and used for
experiments, generally when at 80% confluence. NIH3T3 or
HFK cells were infected with recombinant retrovirus (pLXSN
vector, Clontech, BD, Le Pont Claix, France) expressing non-
tagged HPV16 E7 proteins. In some experiments, NIH3T3 cells
constitutively expressing E7 genes were generated by infection
with pBabepuro vector expressing HPV16 HA-tagged E7 proteins,
wild-type or mutant.
The 2BN11 cell line was created by infecting NIH3T3 cells with
recombinant retrovirus expressing the HPV16 E7 gene under the
control of a tetracycline repressed promoter. The tetracycline-
controlled expression system consisted of regulator and response
elements in a one vector system [48]. Cells were cultured in
DMEM high glucose (4500 mg/l) supplemented with NaHCO3
(3700 mg/l), 10% (v/v) heat inactivated fetal bovine serum, L-
glutamine (2 mM), Na-Pyruvate (1 mg/ml) and 1 mM tetracycline.
The clones, after selection in puromycin, were selected on the basis
of having low basal E7 expression in the presence of tetracycline
and high inducibility as determined by Western blot and RT-PCR
analysis.
Transient transfections with the various mutated cDNAs were
performed with the FuGENE HD Transfection Reagent (Roche)
according to the manufacturer’s instructions [12]. H89, SB203580
and IBMX were purchased from Sigma whereas Forskolin was
from Calbiochem (Novabiochem Corp., La Jolla, CA). The effect
of these clones or pharmacological agents on E7 expression were
tested in an RT-PCR assay as described below and none of them
had any effect on E7 message (Figure S1)
RNA preparation and semiquantitative RT-PCR
Total RNA was extracted from cells using the RNeasy system
(Qiagen, Valencia, CA) and treated with RNAase-free Dnase
(Qiagen) for 15 min at room temperature. Spectrophotometric
ratios of A260 to A280 were greater than 1.8. Total RNA (500 ng)
was reverse transcribed in 20 ml reaction system using Random
Hexamers priming and MuLV Reverse Transcriptase (RT) with
the RNA PCR Kit GeneAmp (Applied Biosystems) under
conditions described by the supplier. Reverse transcription-PCRs
(RT-PCRs) were carried out essentially as previously reported
[12]. Quantification of HPV16 E7 expression levels was
PKA-RhoA-p38 in Transformation
PLoS ONE | www.plosone.org 2 October 2008 | Volume 3 | Issue 10 | e3529performed by comparison to the GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) housekeeping gene. Primer sequences
were as follows: HPV16 E7 gene, 59-ATG CAT GGA GAT ACA
CCT AC-39 (forward) and 59-TAT GGT TTC TGA GAA CAG
ATG-39 (reverse); GAPDH gene, 59-ACC ACA GTC CAT GCC
ATC AC-39 (forward) and 59-TCC ACC ACC CTG TTG CTG
TA-39 (reverse). PCRs for HPV16 E7 and the GAPDH gene were
performed by a touchdown protocol with the following cycling
conditions: 10 min at 95uC (initial denaturation), 6 cycles of step-
down PCR consisting of 45 s at 95uC (denaturation), 60 s at 58uC
(annealing) – decrease 1uC each cycle until 53uC; and 120 s at
72uC (extension). Amplification of the final product was completed
for 26 cycles of 45 s at 95uC, 60 s at 53uC, and 120 s at 72uC, with
a final extension of 10 min at 72uC. In the negative control,
RNase free water (Gibco) was used instead of template RNA. The
positive control included HPV16 E7 cDNA. Amplicons were
separated on 1.5% agarose gel and visualized by ethidium
bromide staining.
NHE1 activity
Intracellular pH was determined spectrofluorimetrically in cells
loaded with the acetoxy-methyl ester derivative of the pH-sensitive
dye 2,7-biscarboxyethyl-5(6)-carboxyfluorescein (AM-BCECF, In-
vitrogen). NHE1 activity was determined by measuring the rate of
pHi recovery from an acid load produced with the NH4Cl
prepulse technique by evaluating the derivative of the slope of the
time-dependent pHi recovery (dpHi/dt) as previously described
[40,48]. The use of CO2/HCO3 free solutions minimizes the
likelihood that Na
+-dependent HCO3 transport was responsible
for the observed pHi changes.
After each experiment trypan blue exclusion was also measured
for each cover slip and when was more than 5% the experiment
was not used.
Construction of expression vectors containing RhoA
mutants
Site-directed mutagenesis of RhoA to create RhoAS188A was
performed by PCR overlap extension as previously described [11].
The successful construction of the mutants was confirmed by DNA
sequence analysis. The cDNA were cloned into the pBabe puro
expression vector containing a hemagglutinin (HA) tag.
RhoA RNA Interference
Small interfering RNA (siRNA) duplex against RhoA (sc-29471)
was obtained from Santa Cruz Biotechnology. The specificity of
the silencing tecnique was verified by using a control, non
targeting 20–25 nucleotide siRNA designed as a negative control
(Control siRNA-A, sc-37007, Santa Cruz Biotechnology). siRNAs
were used at 100 nM concentration and transfection with siRNA
was performed using Lipofectamine 2000 (Invitrogen) 24 hr after
plating cells. The efficiency of RhoA silencing was measured in
immunofluroescence microscopy using a monoclonal anti-RhoA
antibody (sc-418, Santa Cruz Biotechnology) and was found to be
,75% after 72 hrs siRNA treatment (Fig. S2). RhoA expression
levels were measured via pixel density analysis using the WCIF
Image J 1.37c software (Wayne Rasband, NIH, USA). Therefore,
NHE1 activity was analyzed 72 hrs post-transfection with either
RhoA siRNA or control siRNA-A in the presence of tet or 24 hrs
after tet removal.
Adherent cell cAMP assay
Cells (10
4 cells in 100 ml of media) were plated into each well of
a Greiner Bio-one tissue culture grade 96-well white clear bottom
microassay plate (PBI S.p.a., Italy) and incubated in 5% CO2
atmosphere at 37uC for 24 hr. Cells were washed once with 100 ml
of DMEM serum free medium plus 100 mM IBMX and then
treated with 20 mM of FSK and 1 mM of IBMX in 20 mlo f
reaction media at 37uC for 30 min. Levels of cytosolic cAMP were
then measured with the cAMP-Glo
TM assay (Promega, Italy) as
per manufacturers instructions. Briefly, the medium was aspirated,
20 ml of lysis buffer and 40 ml of cAMP-Detection Solution was
added and the plate was incubated with gentle rocking at room
temperature for 20 min. Next, 80 ml of Kinase-Reagent were
added, and luminescence was read after incubation for 10 minutes
in a Fluorescence Spectophotometer Cary Eclipse VARIAN in its
chemiluminescence mode where each well is read for 20 seconds.
Increases in cAMP levels result in decreases in chemiluminescence.
cAMP FRET measurements and cell imaging
For time-lapse FRET experiments, cells were cotransfected with
1.5 mg each of pcDNA3Cat-YFP and pcDNA3RII-CFP plasmids
using Fugene 6 (Roche, Switzerland) for 24 hr as described [51].
Twenty-four hours after transfection, monolayers of cells were
cultured an additional 3 or 24 h in the presence or absence of
tetracycline and imaged on a Nikon ECLIPSE TE 2000-S
equipped with a charge-coupled device camera, a controlled
DeltaRAM monochromator on the excitation side and a beam
splitter (Optical Insight, St. Cloud, MN) on the emission side fitted
with a 505DCRX dichroic and two emission filters, D480/30 and
D535/40. Excitation was at 430 nm and the dichroic mirror was a
455DRLP. Acquisition and FRET analyses were performed using
the Metafluor 4.6 software (Meta Imaging 4.6; Universal Imaging,
Downingtown, PA). The live imaging was done with 464 binning
to minimize exposure time, photobleaching and registration
artifacts. To study agonist-induced changes in FRET: following
the recording of a baseline, cells were first continuously superfused
with the phosphodiesterase inhibitor IBMX (100 mM) and then
treated with a mix of IBMX (100 mM) and the adenylate cyclase
activator forskolin (25 mM). The change in FRET signal due to
mobilization of cAMP was detected by FRET/CFP ratiometric
processing in both non stimulated and agonist-stimulated cells, in
which both FRET (CFP excitation–YFP emission) and CFP (CFP
excitation–CFP emission) images were first background subtract-
ed. Cells were thresholded to discard any portions of the image
with insufficient intensity to provide reasonable signal/noise. The
resulting background-subtracted FRET image was divided by that
of CFP image to obtain a pixel-to-pixel FRET/CFP ratio image
Increasing cAMP levels result in a reduction in FRET ratio (Em
YFP/Em CFP). The final FRET images were displayed in
pseudocolors scaled linearly from the lowest (red) to the highest
(blue) signal to show relative increase in cAMP mobilization of
levels within each cell at each treatment at both 3 and 24 hrs.
Protein extraction and Western blotting
Western Blotting was performed as described [11]. Samples
were extracted in sodium dodecyl sulfate (SDS) sample buffer
(6.25 mM Tris-HCl, pH 6.8, containing 10% (v/v) glycerol,
3 mM SDS, 1% (v/v) 2-mercaptoethanol and 0.75 mM of
Bromophenol Blue), separated by 4–12% SDS-PAGE and blotted
to Immobilon P. Analysis of phospho- and total RhoA was
performed by using an antibody produced against a peptide of
RhoA phosphorylated at serine 188 by PRIMM (Milan, Italy)
diluted 1:1000, against total RhoA (sc-418, Santa Cruz, CA)
diluted at 1:1000, against tubulin (T5293, Sigma) and against the
HA tag (MMS-101R BabCo, diluted 1:200). Molecular weights
standards were ‘Biotinylated Protein Ladder Detection Pack’ (Cell
Signaling Technology, MA).
PKA-RhoA-p38 in Transformation
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For the kinase phosphorylation measurements total cellular
protein was extracted in SDS-sample buffer (50 mM Tris-HCl
pH 6.8, 2% SDS, 10% glycerol and 0.1% bromophenol blue) and
approximately 50 mg was separated on 10% SDS-PAGE and
transfered to Immobilon P, (Millipore). The relative amount of each
phosphorylated kinase (ERK, JNK and p38) to its total expression
was determined by Western Blotting with antibodies specific to each
obtained from Cell Signaling Technology (MA, USA).
p38 MAP kinase activity assay
To assay p38 MAP kinase activity, cells were grown to
approximately 70% confluence in 10 cm plates (GIBCO) and
treated as decribed in figure legends. After treatment, cells were
washed with ice-cold phosphate-buffered saline (PBS) and lysed by
5 minutes at 4uC in lysis buffer (150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate,
1 mM ß-glycerophosphate, 1 mM Na3VO4,1mg/ml leupeptin,
20 mM Tris, pH 7.4) plus 1 mM PMSF. The cells were scraped
into Eppendorf tubes and triturated by sonification. The cell lysate
was centifuged at 4uC for 10 min at 14,000 rpm and the
supernatant collected. Protein levels were equalized by normaliz-
ing them to the protein levels measured before the assay.
p38 MAP kinase activity was quantified using an immune
complex kinase assay kit according to the manufacturer’s protocol
(New England Biolabs). Briefly, cleared lysates were immunopre-
cipitated overnight at 4uC with p38 MAPK antibodies conjugated
to agarose (New England BioLabs). Beads were washed three times
with ice-cold lysis buffer and three times with kinase reaction
buffer (25 mM Tris pH 7.5, 5 mM ß-Glycerolphosphate, 2 mM
DTT, 0.1 mM Na3VO4, 10 mM MgCl2) minus ATP and ATF-2.
The pellet was resuspended in 50 ml kinase reaction buffer plus
200 mM ATP and 10 mg GST-ATF-2 as substrate and incubated
at 30uC for 30 minutes. The reaction was stopped by addition of
26Laemmli buffer. The sample was run on 10% SDS-PAGE and
blotted onto polyvinylidene difluoride membranes (Millipore) for
immunoanalysis. The amount of ATF-2 phosphorylated by p38
was analyzed by Western blotting with a Phospho-ATF-2 (Thr71)
antibody (Cell Signaling) that detects only catalytically activated
ATF-2. Total p38 expression measured by immunoblotting was
not found to vary under any experimental conditions.
Analysis of RhoA serine phosphorylation state
After treatment cell monolayers were washed twice with ice-cold
PBS and lysed in ice-cold RIPA (the above lysis buffer plus 0.1%
SDS and 0.2% Na-deoxycholate). The cellular lysate was
centrifuged at 14,000 rpm for 5 min at 4uC. Protein levels were
equalized by normalizing them to the protein levels measured
before the assay and the supernatent pre-cleared with protein A-
agarose for 2 hrs at 4uC. Cleared lysates were immunoprecipitated
overnight at 4uC with a phosphoserine antibody conjugated to
agarose (SIGMA). The agarose beads were washed four times with
simple RIPA buffer. The pellet was resuspended in 50 ml Laemmli
buffer. The sample was run on 12% SDS-PAGE and blotted onto
Immobilon P (Millipore) for immunoanalysis of the amount of
RhoA immunoprecipitated by antiphosphoserine with a RhoA
antibody (sc-418, Santa Cruz).
Analysis of the activity of RhoA
RhoA activity was assessed using the RhoA-binding domain of
Rhotekin in a kit supplied from Upstate Biotechnology (Lake Placid,
NY). In brief, 3610
6 cells were plated onto 10 cm cell culture dishes
and after 24 hrs treated as indicated. After the indicated time, cells
were extracted with RIPA buffer (50 mM Tris, pH 7.2, 500 mM
NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 1% SDS,
10 mM MgCl2,0 . 5mg/ml leupeptin, 0.7 mg/ml pepstatin, 4 mg/ml
aprotinin, and 2 mM PMSF). After centrifugation at 14,000 g for
3 min, the extracts were incubated for 45 min at 4uCw i t h
glutathione beads coupled with GST–RBD (Rho-Binding Domain
of Rhotekin) fusion protein (Upstate Biotechnology, Lake Placid,
NY), and then washed three times with Tris buffer, pH 7.2,
containing 1% Triton X-100, 150 mM NaCl, and 10 mM MgCl2.
The RhoA content in these samples or in 50 mg protein of cell
homogenate was determined by immunoblotting samples using anti-
RhoA antibody from Santa Cruz (sc-418, Santa Cruz, CA).
FRET assay for RhoA activity
For these experiments, endogenous RhoA activity was mea-
sured in FRET microscopy using the Raichu 1297 probe as
previously described [11]. In this sensor, the Rho Binding Domain
(RBD) of the RhoA effector protein, Rhotekin, is sandwiched by
Venus-YFP and CFP. The binding of endogenous GTP-RhoA to
RBD generates a conformational change that displaces YFP and
CFP, thereby decreasing fluorescence resonance energy transfer
(FRET) efficiency between the two fluorophores, while a reduction
of intracellular active RhoA results in the opposite effect. The CFP
channel images were divided by the YFP-FRET channel images.
The activity of RhoA is monitored by measuring CFP (480 nm)/
YFP(545) fluorescence emission values upon excitation of the
transfected cells at 430 nm. To eliminate the distracting data from
regions outside of cells, the YFP channel is used as a saturation
channel. The ratio images are presented in pseudocolor mode.
Ratio intensity is displayed stretched between the low and high
renormalization value, according to a temperature-based lookup
table with blue (cold) and red (hot) indicating respectively high and
low values of RhoA activity.
Additionally, FRET was used to monitor RhoA activity due to
the activity balance between endogenous guanine nucleotide
exchange factors (GEFs) and GTPase-activating proteins (GAPs):
cells were transfected with a plasmid with the cDNAfor Raichu-
RhoA-1293, which consisted of truncated RhoA (aa 1–189), the
RhoA-binding domain (RBD) of effectors, and a pair of GFP
mutants, YFP and CFP. In these probes, the intramolecular
binding of GTP-RhoA to the effector protein was expected to
bring CFP in closer proximity to YFP, resulting in an increase in
FRET from CFP to YFP.
The set up of the microscope and the filters used for FRET
excitation and emission were identical to those reported for the
cAMP FRET measurements. Briefly, twenty-four hours after
transfection, monolayers of cells were cultured an additional 24 h
in the presence or absence of tetracycline and, images from filter
sets dedicated for YFP, CFP, and FRET fluors were first captured,
and then three to four random regions of interest within each cell,
were chosen for analysis. Sensitized FRET measurements Off-line
image analysis was performed using the Metafluor 4.6 software
(Meta Imaging 4.6; Universal Imaging, Downingtown, PA).
Correction of FRET measurements for spectral bleedthrough
and cross excitation was calculated on a pixel-by-pixel basis for the
entire image by estimating net FRET (nF) as follows: nF=IFRE-
T2(IYFP6a)2(ICFP6b), where IFRET is sensitized YFP emission
(excitation 430 nm, emission 545 nm) and IYFP and ICFP are
YFP emission (545 nm) upon excitation at 480 nm and CFP
emission (480 nm) upon excitation at 430 nm, respectively. a is a
norm of the percentage of CFP bleed-through, and b is a norm of
the percentage of direct excitation of YFP at 430 nm. a and b were
determined by analyzing images of cells expressing only CFP or
YFP as described previously [11], and for our system a and b
PKA-RhoA-p38 in Transformation
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ratio was calculated as ICFP/nF.
Statistical Procedures
In the in vitro experiments, student’s t-test was applied to analyze
the statistical significance between treatments. All comparisons
were performed with InStat (GraphPad Software).
Results
Our goal was to study the signal transduction mechanisms
involved in neoplastic transformation driven by a biologically
relevant oncogene. The E7 oncoprotein of HPV16 is known to
induce transformation both in vitro and in vivo and to fully
transform immortalized rodent fibroblasts (E7/NIH3T3 cells) or
human keratinocytes which are tumorigenic in nude mice [48,50].
HPV16 E7-induced transformation induces down-
regulation of p38 but not JNK or ERK MAPKinase activity
We first determined the effect of HPV16 E7 expression on MAP
Kinase activity by transducing immortalized NIH3T3 cells or
human foreskin kerotinocytes (HFK), the natural host of the virus,
with a recombinant retrovirus expressing non-tagged, wild-type
HPV16 E7 and measuring the phosphorylation state of ERK1/2,
JNK and p38 MAP kinase as described in Material and Methods.
As seen in Figures 1A (NIH3T3) and 1B (HFK), E7 expression
reduced the phosphorylation state of p38 MAP kinase (p38) by
approximately 90% while having no significant effect on the
phosphorylation level of either the ERK or JNK MAP kinases.
The same results were observed in NIH3T3 cells infected with
HA-tagged wild-type E7 (data not shown). Further, two different
protocols were used to determine whether it is simply E7
expression or E7-dependent transformation that leads to an
inhibition of p38. First, we used human primary keratinocytes
(HPKIA cells) immortalized by transfection of the entire HPV16
genome and which become spontaneously transformed at high
passage number and are tumorigenic in nude mice [48,50]. As
shown in Figure 1C, p38 was much less phosphorylated in the
transformed (late passage) keratinocytes than in the immortalized
(early passage) cells while, also here, having no significant effect on
the phosphorylation levels of either the ERK1/2 or JNK MAP
kinases. To further confirm this dependance of p38 dephosphor-
ylation upon HPV-induced transformation, we then extended our
study to NIH3T3 cells infected with recombinant retroviruses
expressing either wild-type HPV16 E7 or transformation-deficient
mutants [53,54]. As seen in Fig. 1D, the wild-type E7 reduced p38
phosphorylation as above while the transformation negative
mutants had no effect on p38 phosphorylation. Altogether, these
results demonstrate that HPV16-induced transformation reduces
the p38 activity through E7 without affecting either the ERK or
the JNK MAP kinases and are consistent with the reported
specificity of p38 in oncogenic processes.
Figure 1. Only HPV16 E7 expression and not other non-transforming HPV types decreases p38 MAPK phosphorylation in both
NIH3T3 cells and human keratinocytes. A. Cell extracts from empty pLXSN vector NIH3T3 cells and HPV16 E7 infected cells were analyzed by
Western Blot for both the phosphorylation state and total expression level of ERK, JNK and p38 MAPK. Western blot analysis was carried out using
polyclonal anti-phospho-ERK1/2, anti-phospho-JNK and anti-phospho-p38 antibodies followed by polyclonal anti-total ERK1/2, total-JNK and total-
p38 MAP Kinase antibodies. Tubulin expression was used as an additional loading control and 500 ng of each sample total RNA were subjected to a
semi-quantitative RT-PCR for HPV16 E7 expression analysis. GAPDH: loading control, pc: positive control, nc: negative control. B. Cell extracts from
empty pLXSN vector HFK cells and HPV16 E7 infected HKF cells were analyzed by Western Blot for both the phosphorylation state and total
expression level of ERK, JNK and p38 MAPK as above. C. Cell extracts from early passage (p94) HPK1A cells and late passage (p396) HPK1A cells were
analyzed by Western Blot for both the phosphorylation state and total expression level of ERK, JNK and p38 MAPK as above. D. NIH3T3 cells were
infected with recombinant retroviruses expressing either empty vector (pBabe), wild type HPV16 E7-Ha tag (WT), or transformation-deficient HPV16
E7-Ha mutants (24, 10, 31/32), and total cell extracts were assayed in Western blot for phosphorylated and total p38 expression levels as above. All
the cell lines expressed E7 as confirmed by using an Ab anti HA-tag (E7-HA). Preliminary experiments demonstrated that the HA tag does not interfer
with the induction of transformation (data not shown).
doi:10.1371/journal.pone.0003529.g001
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event in transformation
The above experimental systems do not permit the determination
of the dynamic processes occurring during transformation. To
determine whether inhibition of p38 is an early event in
transformation, a cell model was constructed in which the
transformation of normal cells can be rapidly induced and early
events subsequently monitored. NIH3T3 cells were infected with a
recombinant retrovirus in which HPV16 E7 gene expression is
under the control of a promoter that is negatively regulated by
tetracycline, clone 2BN11 [48]. The temporal sequence of the
increase in E7 message (Fig. 2A) and the change in p38
phosphorylation state (Fig. 2B) and in activity, measured as the
phosphorylationofitssubstrate,ATF2,(Fig.2C)wasmonitoredafter
induction of E7 expression. These experiments showed that the
increase in E7 mRNA and reduction of both p38 phosphorylation
and activity levels started approximately 2–3 hrs after tet removal,
which is in agreement with the previously observed time course for
the appearance of E7 mRNA and protein [48].
HPV16 E7 expression activates the cAMP pathway
As the cAMP/PKA system has been demonstrated to be
involved in both transformation/tumor progression [12,35,55,56]
and regulation of p38 [57], we next measured the effect of E7-
driven transformation on the levels of cellular cAMP at both early
(3 hrs) and late (24 hrs) time points after tet removal. We started
with a biochemical assay in which the bioluminescence intensity
level inversely correlates with cAMP intracellular mobilization (see
Materials and Methods). Cells were first treated with 100 mMo f
the phosphodiesterase inhibitor, IBMX, in order to observe the
activity level of endogenous adenylate cyclase and then were
treated with IBMX together with 20 mM of the pharmacologic
adenylate cyclase activator, forskolin, to determine the dynamic
range of increasing activity of the remaining non E7-stimulated
enzyme. The left panel of Figure 3A shows a much greater
decrease of bioluminescence after inhibition of intracellular
phosphodiesterases by IBMX in the E7-transformed cells (2tet)
while the subsequent decrease of bioluminescence after addition of
the adenylate cyclase stimulator, forskolin, was similar in control
and transformed cells. Calculation of cAMP concentration with a
standard curve showed that transformation increased cellular
cAMP levels (measured in the presence of IBMX), by approxi-
mately 2.5-fold at 3 hrs and 5-fold at 24 hrs without increasing
total potential adenylate cyclase activity (Figure 3A right panel).
Interestingly, a similar rise in cAMP was observed in late passage
compared to early HPK1A cells and, further, blockage of NHE1
activity with 2 mM of its specific inhibitor, HOE642, had no effect
on this E7-induced increase in cAMP in either 2BN11 or HPK1A
cells (Figure S3).
To further verify this specific stimulation of cAMP mobilization in
response to HPV16 E7 expression and visualize cAMP dynamics in
vivo, we transfected 2BN11 cells with a PKA-based FRET construct
composed of green fluorescent protein variants bound to either the
PKA catalytic subunit (Cat-YFP) or the PKA regulatory II subunit
(RII-CFP) and recorded FRET images with a dual-emission CCD
camera. Increased levels of cAMP produce a decrease in FRET
signal, measured as YFP-to-CFP emissions ratio, due to cAMP
binding to the chimericPKA reporterandtheresultantseparation of
the catalytic and regulatory subunits. In time course experiments,
when the cAMP signal was stable, cells were first treated with IBMX
in order to observe the activity level of endogenous adenylate cyclase
and then were perfused with IBMX together with forskolin to
determine the dynamic range of increasing activity of the remaining
non E7-stimulated enzyme. As can be seen in Figure 3B, IBMX
superfusion stimulated cAMP production approximately 2-fold at
3 hrs and 4.5-fold at 24 hrs in the E7 transformed cells compared to
the control cells, while the further cAMP elevation after forskolin
(FSK) treatment was similar in both conditions. Altogether, these
datasuggest that, indeed,transformation ofthe cells byE7stimulates
adenylate cyclase-dependent production of cAMP above very low
basal levels in the control cells. Figure 3C shows the relative increase
in cAMP mobilization as pseudocolor changes in typical FRET
experiments.
Involvement of PKA and p38 in HPV16 E7-mediated
transformation
To assess the role and dynamics of PKA and p38 in mediating
transformation, we utilized changes in NHE1 activity as the
transformation readout because we have previously demonstrated
that stimulation of NHE1 occurs early in transformation and is
necessary and sufficient for the further development of trans-
Figure 2. Time course of changes in HPV16 E7 expression and
both phosphorylation and activity of p38 MAPK in 2BN11 cells
after tetracycline (tet) removal. A. The activation of HPV16 E7
transcription upon tet removal from the culture medium was
determined by RT-PCR as described in in Materials and Methods. After
tet removal the cells were collected at the indicated times, total RNA
prepared, cDNA generated and the levels of message were determined.
The levels of GAPDH were also determined in each sample as internal
control. nc: negative control in which the PCR was performed in the
absence of a template; pc: positive control included HPV16 E7 cDNA as
template. B. Time course of HPV16 E7 expression-dependent inhibition
of p38 phosphorylation, total p38 and tubulin in 2BN11 cells after
tetracycline removal. C. p38 activity during HPV16 E7 expression (tet
removal) was determined by exposing p38 immunoprecipitated from
1 mg of cell lysate to 10 mg GST-ATF-2 as described in methods. The
amount of ATF-2 phosphorylated by p38 was analyzed by Western
Blotting with an Phospho-ATF-2 (Thr71) antibody and tubulin levels in
the homogenate was used as loading control.
doi:10.1371/journal.pone.0003529.g002
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PLoS ONE | www.plosone.org 6 October 2008 | Volume 3 | Issue 10 | e3529Figure 3. HPV16 E7 expression stimulates cAMP generation in 2BN11 cells. To determine the effect of E7 expression on cAMP production,
cAMP levels were measured using A. the biochemical luciferase-based Kinase-Glo System where luminescence is inversely proportional to cAMP
levels (for details see Methods). Cells were cultured with or without tet for either 3 or 24 hr and then either not treated (dark bars) or treated for
30 min with either 100 mM IBMX (light bars) or 100 mM IBMX plus 20 mM FSK (stippled bars). Left panel shows levels of luminescence in the various
treatments while right panel shows the calculated increase in cAMP concentration with each treatment. Error bars represent the standard error of the
mean (SEM) of three independent experiments. B. Time-lapse FRET imaging in live cells transfected with a PKA-based FRET probe, in which cyan and
yellow mutants of GFP have been fused to its regulatory and catalytic subunits, respectively, so that cAMP-induced dissociation between the two is
detected as FRET changes. Cells were transfected with the FRET cAMP biosensor for 24 hrs and then cultured with or without tet for either 3 or 24 hr.
Cells were mounted in a perfusion chamber and the FRET ratio measured during superfusion with ringer alone followed by superfusion first with
100 mM IBMX and then 100 mM IBMX plus 20 mM FSK. Cells were imaged for CFP and YFP every 20 s and the YFP/CFP emission ratios (FRET ratios)
obtained. Left panel shows levels of YFP/CFP emission ratios in the various treatments while right panel shows the calculated increase in YFP/CFP
emission ratios with each treatment which is relative to increases in cAMP production. Data are the mean6SEM from 32 different cells. C.
Pseudocolor images representing YFP/CFP emission ratios recorded under control conditions (plus and minus tet for either 3 or 24 hrs), after
exposure to 100 mM IBMX and after stimulation with IBMX (100 mM) plus FSK (20 mM). Each image was scaled according to its high and low values at
each time point to show relative level of cAMP at each time point. The dynamic range was 0.9–1.3. Warmer colors correspond to lower cAMP levels.
doi:10.1371/journal.pone.0003529.g003
PKA-RhoA-p38 in Transformation
PLoS ONE | www.plosone.org 7 October 2008 | Volume 3 | Issue 10 | e3529formed phenotypes [48]. As seen in Figure 4, the induction of
cellular E7 expression and transformation by removal of
tetracycline for 24 hrs stimulated NHE1 activity by 69.566.2%,
n=15, P,0.02 (blue cross-hatched bar) and this stimulation was
blocked by 2 mM of the specific inhibitor of the NHE1, HOE642
(data not shown). Inhibition of PKA by its specific inhibitor, H89,
completely abrogated the transformation-dependent increase in
NHE1 activity (green stippled bar) while inhibition of p38 activity
by either its pharmacological inhibitor, SB203580, or by the
transient expression of the dominant negative (dn) mutant for
p38alpha (p38AF) further potentiated the transformation-depen-
dent increase in NHE1 activity by approximately 2-fold (black
stripped bars). Furthermore, inhibition of p38 either with
SB203580 or via transient expression of dnp38alpha blocked the
abrogation of the transformation-dependent activation of NHE1
by H89 (red stripped bars). These data strongly suggest that PKA
and p38alpha are part of the same pathway in regulating the
transformation-dependent stimulation of NHE1 and that PKA is
up-stream of p38. This conclusion is further supported by the
ability of H89 to block and forskolin (Fsk) to potentiate the E7-
dependent down-regulation of p38 phosphorylation (Figures 4B &
C) while having no effect on the phosphorylation state of JNK and
ERK (Figure S4).
HPV16 E7-dependent transformation induces PKA-
dependent phosphorylation and down-regulation of
RhoA
However, the steps that mediate the down-regulation of p38 by
PKA still need to be identified. RhoA is a potential candidate since
it has been shown to be an upstream regulator of p38 in enhancing
migration and invasion of breast cancer [11] and pancreatic
carcinoma cells [32] and to be inhibited by PKA-dependent
phosphorylation on serine 188 [11,58]. If this is occurring during
transformation then we would expect RhoA to be phosphorylated
by PKA and to be inhibited by E7-dependent transformation. To
test this hypothesis, we first measured the effect of transformation
on the phosphorylation state of RhoA via Western Blotting
analysis with antibodies specific for phosphorylated Ser-188 of
RhoA (Fig. 5A) or via co-immunoprecipitation with anti-
phosphoserine followed by anti-RhoA Western Blotting (Fig. 5B)
at different times of HPV16 E7 expression (t0, 1 hr, 3 hr, 6 hr,
12 hr). Indeed, transformation induced a significant increase in
RhoA phosphorylation in 2BN11 cells. A similar increase in RhoA
phosphorylation was observed in E7 expressing HFK cells and late
passage HPK1A cells (Figure S5) and blockage of NHE1 actvity
with HOE642 had no effect on this process in either 2BN11 or
HPK1A cells (Figure S3). To verify that this phosphorylation of
RhoA observed upon transformation was due to PKA, we
removed tet for 24 hrs in the absence or presence of a
pharmacological PKA inhibitor (H89, 100 nM) or activator
(forskolin, 10 mM) and we measured RhoA phosphorylation as
above with the anti-phosphoSer188. The induction of phosphor-
ylation was blocked by incubation with H89 and potentiated by
incubation with forskolin (Fsk) during the time of induction of E7
expression (Fig. 5C).
As PKA can inhibit RhoA activity via its phosphorylation of
serine 188, we next examined the effect of transformation on
RhoA activity, first by a pulldown analysis of its binding to GST-
fusion protein to the Rho binding domain of Rhotekin which
associates preferentially with GTP-bound RhoA [59]. Figure 6A
shows that the activity of RhoA was reduced upon E7-dependent
transformation with a time course similar to that reported for the
up-regulation of NHE1 activity by the same treatment [48] and for
RhoA phosphorylation shown above and that H89 treatment
blocked while forskolin (Fsk) treatment stimulated this reduction in
RhoA activity. However, the biochemical detection of active
RhoA via pull-down requires cell disruption and is performed in
the presence of detergents which can lead to dissociation of
preexisting complexes and, therefore, cause incorrect estimation of
the extent of RhoA-GTP association to its down-stream effectors.
In contrast, FRET microscopy permits the direct detection of the
amount of active RhoA in intact living cells during E7-
transformation. For this reason, we next measured RhoA activity
state by using a a single-chain CFP/YFP FRET biosensor for
RhoA (pRaichu 12976) [60], which directly monitors the level of
the endogenous RhoA-GTP by measuring FRET between the two
pairs of GFP mutants fused to the Rho-Binding-Domain (RBD) of
Rhotekin. Specifically, in this probe the binding of endogenous
GTP-RhoA to RBD displaces YFP and CFP, thereby decreasing
FRET efficiency. Using this FRET-based probe we verified that
24 hrs after tet removal, RhoA activity, which was assessed as the
ratio of the CFP signal to the YFP signal, was significantly reduced
(Figure 6B). Further, treatment with H89 during the transforma-
tion period completely reversed this E7-dependent inhibition of
RhoA, again indicating that E7-induced RhoA inhibition was
dependent on PKA.
In addition to phosphorylation by PKA, RhoA activity is
controlled by the activity balance between other class of RhoA
regulating proteins, the guanine nucleotide exchange factors
(GEFs) and GTPase-activating proteins (GAPs) [29]. To assess if
E7 alters the balance of GEFs and GAPs thus changing RhoA-
GTP loading, we monitored the relative level of GEFs and GAPs
in the presence and absence of tet for 24 hr, by using another
FRET probe, pRaichu 12936, consisting of a chimera of RhoA
and the RhoA binding domain (RBD) of PKN, sandwiched
between YFP and CFP. The relative increase in GEF activity
increases the amount of GTP-RhoA and the intramolecular
binding of GTP-RhoA to RBD and brings CFP in close proximity
to YFP, resulting in an increase in FRET from CFP to YFP [60].
With this probe, we did not find any difference in the FRET ratio
during E7-dependent transformation (0.860.031 vs 0.7960.030,
n=20, n.s., for +tet and 2tet, respectively) demonstrating that
transformation did not influence GEF or GAP activity. These data
suggest that a PKA-dependent phosphorylation of RhoA is the
critical mechanism of E7 induced-RhoA inhibition.
HPV16 E7 expression activates NHE1 through a reduction
in RhoA activity via its phosphorylation on serine 188
While the preceding experiments indicate that RhoA is a
substrate for PKA in these cells and that its phosphorylation at
serine-188 is increased with E7-driven transformation, a critical
question in the context of the current study is if the observed PKA-
dependent phosphorylation and inhibition of RhoA is necessary
for the transformation-dependent up-regulation of NHE1 activity.
The phosphorylation of RhoA at serine 188 by PKA has been
shown to block its action [46,61], suggesting that this serine could
be the PKA target also in our case. Therefore, as an approach to
assess the role of PKA-dependent phosphorylation of RhoA in the
activation of NHE1, we mutated the PKA phosphorylation site,
serine188, to alanine to create a PKA phosphorylation dead (pd)
RhoA mutant [11,12]. Transfection of control 2BN11 cells with
this pd RhoA
S188A mutant did not affect basal NHE1 activity
levels of +tet cells, while it completely abrogated the increased
NHE1 activity induced by expression of HPV16 E7 (Figure 6C,
blue cross-hatched bars), confirming the requirement for PKA-
dependent phosphorylation of RhoA at serine 188 for the up-
regulation of NHE1 activity by E7-dependent transformation. We
next determined if it is the alteration in RhoA activity utilizing
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PLoS ONE | www.plosone.org 8 October 2008 | Volume 3 | Issue 10 | e3529Figure 4. PKA is up-stream of p38 in regulating the HPV16 E7 expression-dependent stimulation of NHE1 activity. A. HPV16 E7
expression was induced by removing tetracycline from the culture medium for 24 hrs and the consequences on NHE1 activity of the specific
inhibition for 24 hrs of PKA by 10
27 M of its specific inhibitor, H89, and/or p38 by either 10
29 M of its specific pharmacological inhibitor, SB203580, or
by the transient expression of a dominant negative (dn) mutant for p38alpha (p38AF, 3 mg) was determined by spectrofluorometry using the pH
sensitive probe BCECF-AM. Confluent monolayers were loaded with BCECF and placed in the perfusion cuvette and the monolayer perfused with
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mutants [11] and/or expression utilizing an siRNA against RhoA
that underlies stimulated NHE1 activity in transformed cells.
Transient transfection of these constructs or the siRNA had no
effect on NHE1 activity in +tet cells. Both inactivation of RhoA
with the dn N19RhoA mutant (Figure 5C, green stippled bars) or
the knock-down of its expression (Figure 6C, brown reverse
stippled bars) significantly potentiated the E7-induced stimulation
of NHE1 activity while activating RhoA with the ca V14RhoA
mutant reduced this stimulation by approximately 80% (Figure 6C,
red striped bars).
Altogether, these data demonstrate that the PKA-dependent
phosphorylation of RhoA is a critical mechanism of HPV16 E7
induced-RhoA inhibition and it is an integral part of the PKA to
p38alpha signal transduction module involved in the activation of
the NHE1 during transformation.
Discussion
There still is a dearth of data concerning the very early signal
transduction events regulating neoplastic transformation- the first
step of the carcinogenic process that is limited to the altered cell. The
elucidation of theunderlying alterations insignaltransduction events
mediating the initiation, development and regulation of transforma-
tion is a necessary prerequiste for understanding the origin and early
development of cancer. As discussed in [17], to accomplish this it is
necessary to use an experimental model in which the transformation
of a normal, immortalized cell by a single oncogene can be highly
controlled, thus permitting the dissection of the sequence of events
occuring after the initial alteration and the role of a particular gene
or signal transduction pathway. These cells, unlike cancer-derived
cell lines, have not aquired genomic instability nor unspecific genetic
and epigenetic alterations that can mask the specific transformation-
dependent alterations.
We utilized this type of inducible cell model with the E7
oncogene of HPV16 to dissect the sequence of the very early steps
in signal transduction underlying ‘‘the moment’’ in which a still
normal cell becomes transformed. To accomplish this, NIH-3T3
cells were transfected with a construct in which E7 gene expression
is under the control of a promoter that is negatively regulated by
tetracycline so that E7 is expressed only after tetracycline removal
[48] (clone 2BN11). Using this model system, we previously
reported that the development of transformed phenotypes (e. g.
increased proliferative rate, anchorage-independent growth, serum
independence and increased glycolytic metabolism) are under the
strict control of E7 expression in these cells and, further, that
intracellular alkalinization driven by an up-regulation of the Na
+/
H
+-exchanger (NHE1) is a very early physiological event in
transformation and which, in turn, is necessary for the develop-
ment and maintenance of many of the cellular events occurring
later in the transformation process such as serum independence,
increased growth rate, anchorage-independent growth and in vivo
tumour development in nude mice. For this reason, we here
utilized changes in NHE1 activity as the readout for the analysis of
the role of a particular signal transduction pathway in transfor-
mation in the dissection of the early signaling events occurring up-
stream of NHE1 activation during E7-dependent transformation.
This experimental model enabled us to recognise and follow a
strictly defined sequential progression arising from the initial
expression of E7 that rapidly transforms the cells. Our data
demonstrate that an intracellular mobilization of cAMP is one of
the first signaling events occurring during transformation (Figure 3).
Further,weprovideevidencethat thisinitialriseincAMPisfollowed
by a PKA-dependent inhibition of RhoA activity (Figures 6A and
6B) which is necessary for the inactivation of p38alpha (Figure 4B)
and which, in turn, regulates the subsequent E7-mediated
transformation–dependent early stimulation of NHE1 activity
(Figures 4A and 6C). Although the individual importance of each
of these signal systems in tumor induction both in vitro and in vivo is
well documented, their interrelations in mediating transformation
were heretofore still unknown.
Indeed, while there is now much data demonstrating the tumor
suppressor role of p38 MAP Kinase (see introduction), to date it has
not been demonstrated whether the down-regulation of p38alpha
plays a role in the early induction of cellular events leading to
transformation. Further, if it is involved in transformation, we asked
at which point is it located in the transformation process, which up-
stream mechanisms regulate its inhibition and what is its down-
stream target. We first demonstrated in NIH3T3 cells and in human
primary (HPK1A) and secondary (HFK) keratinocytes that E7-
dependent transformation specifically reduces p38 phosphorylation.
Then, using the inducible experimental model we show that
p38alpha plays a key role in the acquisition of the increased activity
of the NHE1 which sets the stage for the development of the other
transformed phenotypes [48]. Interestingly, p38alpha has also been
found to have a negative role in regulating both migration and
invasion of pancreatic and breast carcinoma cells [11–12,32] and its
activity is reduced in hepatocellular carcinomas in comparison to
adjacent normal tissue [62], suggesting that its down-regulation is
not limited to just transformation and early tumorigenesis but also in
later metastatic/aggressive stages.
The involvement ofthecAMP/PKApathwayinmediating tumor
progression [35] together with the demonstrated integration of p38
with cAMP/PKA signaling in different cell systems [43,57,63,64]
focused our attention on the possibility that E7 transformation-
dependent down-regulation of p38 involves the cAMP/PKA system.
Transformation induced substantial increase in adenylate cyclase-
dependent cellular cAMP mobilization (Fig. 2) and incubation with
the PKA selective inhibitor, H89, during E7-dependent transforma-
tion blocked the down-regulation of p38 phosphorylation while
stimulation of the cAMP/PKA system by forskolin (Fsk) enhanced
this E7-dependent down-regulation of p38 phosphorylation (Fig. 4B
and 4C). Further, inhibition of p38 with either SB203580 or via
transient expression of a dominant negative p38alpha mutant (dn
p38alpha) blocked the H89-dependent abrogation of the transfor-
mation-dependent activation of NHE1 (Figure 3A), further support-
135 mM Na
+ nominally bicarbonate free-HEPES ringer (pH 7.4) plus (Cont) or minus (E7) 2 mM tetracycline as previously described [48]. To analyze if
PKA and p38 interact one each other in regulating NHE1 activity, cells were either first transfected with dnp38 for 48 hrs and then treated with H89
for 24 hrs or were simultaneosly treated with SB plus H89 for 24 hrs and NHE1 activity determined as above. Bars are mean6S.E. and the number of
experiments ranged from 5 to 8. B. Non transformed (+tet) and transformed (2tet) cells were not treated (Cont) or treated with either 10
27 M H89 or
1025 M FSK for 24 hrs and cells were homogenized as described in Materials and Methods. Aliquots containing 50 mg of protein were subjected to
10% SDS-PAGE and total and phosphorylated p38 was determined in Western Blot as in Figure 1. A representative immunoblot is shown. C.
Summarized data of densitometrical analyses of p38 phosphorylation is represented as the relative ratio of the density of phospho-p38 against that
of total p38. Relative ratio in control, non transformed cells was expressed as 1 arbitrary unit. Control cells are represented by dark bars, H89 treated
cells by stippled bars and Fsk treated cells by cross-hatched bars. The data shown are mean values6S.E. (n=4). p,0.05 (*) and p,0.01 (**) when
compared with the control value by Student’s t test.
doi:10.1371/journal.pone.0003529.g004
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and functionally to a common signalling unit, inwhichPKA acts up-
stream to p38 in regulating the transformation-dependent stimula-
tion of NHE1 activity.
As RhoA is known be a PKA-signalling effector in a plethora of
cell responses [11,58,44] and to play an important role in
regulating p38 kinase activity in several cellular regulatory contexts
[11,32,63,64], we analysed its involvement in underlying the
down-regulation of p38 by PKA and in their regulation of E7-
dependent activation of NHE1. We observed that RhoA was
rapidly phosphorylated at Ser-188 upon E7 expression (Figs. 4A &
B) and PKA is involved in this phosphorylation since inhibition of
the kinase with H89 or its stimulation by forskolin (Fsk) during the
time of induction of E7 expression respectively blocked or
potentiated the E7-induced phosphorylation (Fig. 4C). Further,
RhoA was inhibited upon E7 expression with a time course
parallel to its E7-induced phosphorylation (Figures 6A & B) and
inhibition of PKA by H89 reversed the decrease in RhoA activity
only in transformed cells (Figure 6B). Interestingly, FRET
measurements of Rho-GEFs/GAP activity revealed that the
inhibition of RhoA via changes in their activity could be excluded
during E7 transformation. Altogether these data suggest that the
PKA that is activated in HPV16 E7 transformed cells inhibits RhoA
activity through its phosphorylation of RhoA at serine 188. RhoA
has been recently reported to be inhibited as a result of
transformation driven by TGFbeta [67] or, importantly, HPV16
E7 expression [33] suggesting that this might be a common
mechanism. An important question was if the observed PKA-
dependent phosphorylation and inhibition of RhoA is necessary for
the transformation-dependent up-regulation of NHE1 activity.
Analysis of NHE1 activity after transfection of a dn RhoA mutant
or siRNA to block RhoA function/expression or a ca RhoA mutant
toenhanceRhoA function(Figure6C)demonstratedthe importance
of the inhibition of RhoA activity in E7 transformation-induced
NHE1 activity while transfection of the phosphodead (pd) RhoA
mutant revealed the important role for its PKA-dependent
phosphorylation in E7 transformation-induced NHE1 activity.
The activity of many enzymes is strictly controlled by intracellular
pH (pHi) and, therefore, an important question is what extent this
E7-induced signal cascade described herein might be altered via
feedbackbythe changesinpHi drivenbythe stimulatedNHE1[48].
To address this question, we measured cAMP production,
phosphorylation of RhoA and the inhibition of p38 in the presence
and absence of 2 mM HOE642,a potent and specific inhibitor of the
NHE1,inboth2BN11cellsandinearlyandlatepassagesofHPK1A
cells. This treatment has been previously shown to block the
development of phenotypes down-stream of the NHE1 in both cell
lines [48]. As can be seen in Figure S3, this treatment had no effect
on any of these process in either of the cell lines suggesting a strict
unidirectionality of this signal cascade both in the rat fibroblast and
human keratinocyte models.
In conclusion, in this study we have recognised a strictly defined
sequential progression arising from the initial expression of E7 that
rapidly transforms the cells. Our data demonstrate that an
intracellular mobilization of cAMP is one of the first signaling
events occurring during transformation and that this initial rise in
cAMP is followed by a PKA-dependent inhibition of RhoA
activity which is necessary for the inactivation of p38alpha which,
in turn, regulates the subsequent E7-mediated transformation–
dependent early stimulation of NHE1 activity. An important
question is whether this signal cascade is engaged by simple E7
expression or is transformation dependent. The data in Figure 1D
shows that only transformation competent E7 is able to inhibit p38
and the use of the HPK1A model system in this study, in which the
original viral infection (early passage) simply immortalizes the cells
and with time they become transformed (late passage), further
validated the concept of transformation specific effects. Impor-
tantly, finding the same signal transduction cascade turned on in
the late passage HPK1A cells also demonstrated that this signal
cascade is engaged during the natural progression of primary
human keratinocyte cells that were infected with the actual
HPV16 virus and is not just a consequence of the expression of a
Figure 5. HPV16 E7 induces PKA-dependent phosphorylation
of RhoA. A. Western Blotting analysis of the phosphorylation state of
RhoA at different times after tet removal (+tet, 1 hr, 3 hr, 6 hr and
24 hr) with antibodies specific for phosphorylated Ser-188 of RhoA
(phospho RhoA) followed by polyclonal anti-RhoA antibody (total
RhoA). B. Co-immunoprecipitation with anti-phosphoserine antibody
followed by anti-RhoA Western Blotting (phospho RhoA) at different
times of HPV16 E7 expression (t0, 1 hr, 3 hr, 6 hr, 24 hr). Expression of
total RhoA in cell lysates was analyzed by immunoblot analysis using
the polyclonal anti-RhoA antibody. C. To test if RhoA-phosphorylation
induced by HPV16 E7 expression was dependent on PKA, tetracycline
was removed and the cells either not treated or treated with either the
pharmacological PKA inhibitor (H89, 100 nM) or activator (forskolin,
10 mM) and RhoA phosphorylation was measured as above (A).
doi:10.1371/journal.pone.0003529.g005
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[48]. The elucidation of these signal transduction systems and,
more importantly, their interrelations in the early stages of the
HPV-dependent transformation processes could provide indica-
tions for novel therapeutic strategies and/or a potential marker
test for the clinical determination of pre-cancer, HPV-transformed
cells in the cervix.
Supporting Information
Figure S1 Effect of pharmacological treatment and transfection
of cDNA plasmids on E7 message expression by RT-PCR analysis.
2BN11 cells were treated with each of the pharmacological agents
or transfected with the indicated cDNA encoding vectors as
described in Results. RNA was extracted and 500 ng of each
sample total RNA were subjected to a semi-quantitative RT-PCR
for HPV16 E7 expression analysis. GAPDH: loading control.
Found at: doi:10.1371/journal.pone.0003529.s001 (0.07 MB TIF)
Figure S2 Analysis by immunofluorescence microscopy of the
decrease in RhoA expression by RNAi in 2BN11 cells. A. Cells were
transfected with either control, non-targeting siRNA (left panel) or
RhoA specific siRNA (right panel) as described in Materials and
Methods. RhoA was visualized with Alexa Fluor 488 (green) and the
nuclei with DAPI (blue). B. Quantification of the intensity of RhoA
signals through the cell area normalized to cell number. Data
represent mean6SE of three independent experiments.
Found at: doi:10.1371/journal.pone.0003529.s002 (1.35 MB TIF)
Figure S3 Monolayers of either 2BN11 or HPK1A were treated
or not with 2 mM of the specific NHE1 inhibitor, HOE642, and
analyzed for cAMP, phospho-RhoA or phospho-p38 levels as
described in Materials and Methods. In 2BN11 cells the
measurements were made in the presence of tetracycline (+tet)
or 3 or 24 hours after its removal while in HPK1A cells the
comparison was between early and late passage cells.
Found at: doi:10.1371/journal.pone.0003529.s003 (0.21 MB TIF)
Figure S4 Non transformed (+tet) and transformed (2tet) cells
were not treated (Cont) or treated with either 1027 M H89 or
1025 M FSK for 24 hrs and cells were homogenized as described
in Materials and Methods. Aliquots containing 50 mg of protein
were subjected to 10% SDS-PAGE and total and phosphorylated
JNK (upper blot) or ERK1/2 (lower blot) was determined in
Western Blot as in Figure 1. A representative immunoblot is shown
for each MAP kinase.
Found at: doi:10.1371/journal.pone.0003529.s004 (0.39 MB TIF)
Figure S5 Western Blotting analysis of the phosphorylation state
of RhoA in HFK or HPK1A cells with antibodies specific for
phosphorylated Ser-188 of RhoA (phospho RhoA) followed by
polyclonal anti-RhoA antibody (total RhoA). A representative
immunoblot is shown for each. HFK cells were infected with
empty pLXSN vector or pLXSN vector containing wild-type, non-
tagged E7 while HPK1A early passage cells were compared with
late passage cells.
Found at: doi:10.1371/journal.pone.0003529.s005 (0.13 MB
DOC)
Figure 6. HPV16 E7 expression activates NHE1 via a PKA-
mediated-reduction in RhoA activity. A. Representative Western
Blot of three GST-RBD pull-downs showing RhoA activity in 2BN11 cells
at different times after tet removal and treated with 100 nM H89 and
10 mM FSK for the indicated times. The lower gel shows the amount of
total RhoA in cell lysates. B. Sensitized FRET measurements of 2BN11
cells to determine the effect of E7 expression on RhoA activity in live
cells. Cells were transfected with the RhoA biosensor pRaichu-12976
and then cultured with or without tet for 24 hr and treated or not with
100 nM H89 during the 24 hr period. Cells were imaged for CFP and
FRET and the relative decreases in CFP/FRET ratios obtained (presented
in the central column) indicate a decrease in active RhoA. Data are the
mean6SEM from 32 to 37 different cells. ***P,0.005. CFP/FRET ratio
images are in pseudocolor, with the color indicating the relative value
at each pixel (lateral images), such that blue indicates the highest
EmCFP/EmYFP ratio (highest RhoA activity), and red reflects the lowest
EmCFP/EmYFP ratio (lowest RhoA activity). Scale bar is 10 mm. C. Role
of PKA-mediated RhoA signalling on HPV16 E7-induced up-regulation
of NHE1 activity. 2BN11 cells were transfected transiently with cDNA for
either a phosphorylation dead (pd) RhoA mutant (blue cross-hatched
bars), with dominant negative RhoA (dn) mutant (green stippled bars),
with constitutively active RhoA (ca) (red striped bars) mutant or with
siRNA against RhoA (brown reverse stippled bars). Control cells were
transfected with the empty plasmid or non-specific siRNA transfected
cells (scrambled) served as the control for RhoA silencing. After 24 hrs
for cDNA construct or 48 hrs for siRNA transfection, tetracycline was
then removed (2tet) or not (+tet) for a further 24 hrs and NHE1 activity
was measured as described in Materials and Methods. Expression of
these constructs had no effect on basal NHE1 activity in control, +tet
cells. Inactivation of RhoA with the dn mutant and siRNA significantly
potentiated the E7-induced stimulation of NHE1 activity while both
activation of RhoA with the ca mutant and the block of RhoA
phosphorylation by PKA with the pd mutant abrogated the E7-induced
stimulation of NHE1 activity. Efficiency of siRNA-mediated RhoA knock-
down was analyzed with immunofluorescence assay by using a
monoclonal anti-RhoA antibody (green) and the blue fluorescent dye
DAPI for staining nuclei (Figure S2).
doi:10.1371/journal.pone.0003529.g006
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